299 related articles for article (PubMed ID: 33709491)
1. Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies.
Ye F; Zhao J; Xu P; Liu X; Yu J; Shangguan W; Liu J; Luo X; Li C; Ying T; Wang J; Yu B; Wang P
Angew Chem Int Ed Engl; 2021 Jun; 60(23):12904-12910. PubMed ID: 33709491
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 spike protein receptor-binding domain N-glycans facilitate viral internalization in respiratory epithelial cells.
Zheng L; Ma Y; Chen M; Wu G; Yan C; Zhang XE
Biochem Biophys Res Commun; 2021 Nov; 579():69-75. PubMed ID: 34592572
[TBL] [Abstract][Full Text] [Related]
3. Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies.
Rattanapisit K; Bulaon CJI; Khorattanakulchai N; Shanmugaraj B; Wangkanont K; Phoolcharoen W
PLoS One; 2021; 16(8):e0253574. PubMed ID: 34379620
[TBL] [Abstract][Full Text] [Related]
4. Site-specific characterization of SARS-CoV-2 spike glycoprotein receptor-binding domain.
Antonopoulos A; Broome S; Sharov V; Ziegenfuss C; Easton RL; Panico M; Dell A; Morris HR; Haslam SM
Glycobiology; 2021 Apr; 31(3):181-187. PubMed ID: 32886791
[TBL] [Abstract][Full Text] [Related]
5. Structural basis of severe acute respiratory syndrome coronavirus 2 infection.
Ge J; Zhang S; Zhang L; Wang X
Curr Opin HIV AIDS; 2021 Jan; 16(1):74-81. PubMed ID: 33186231
[TBL] [Abstract][Full Text] [Related]
6. Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia.
Asarnow D; Wang B; Lee WH; Hu Y; Huang CW; Faust B; Ng PML; Ngoh EZX; Bohn M; Bulkley D; Pizzorno A; Ary B; Tan HC; Lee CY; Minhat RA; Terrier O; Soh MK; Teo FJ; Yeap YYC; Seah SGK; Chan CEZ; Connelly E; Young NJ; Maurer-Stroh S; Renia L; Hanson BJ; Rosa-Calatrava M; Manglik A; Cheng Y; Craik CS; Wang CI
Cell; 2021 Jun; 184(12):3192-3204.e16. PubMed ID: 33974910
[TBL] [Abstract][Full Text] [Related]
7. The basis of a more contagious 501Y.V1 variant of SARS-CoV-2.
Liu H; Zhang Q; Wei P; Chen Z; Aviszus K; Yang J; Downing W; Jiang C; Liang B; Reynoso L; Downey GP; Frankel SK; Kappler J; Marrack P; Zhang G
Cell Res; 2021 Jun; 31(6):720-722. PubMed ID: 33893398
[No Abstract] [Full Text] [Related]
8. Silico analysis of interaction between full-length SARS-CoV2 S protein with human Ace2 receptor: Modelling, docking, MD simulation.
Rui L; Haonan L; Wanyi C
Biophys Chem; 2020 Dec; 267():106472. PubMed ID: 32916377
[TBL] [Abstract][Full Text] [Related]
9. An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2.
Williams-Noonan BJ; Todorova N; Kulkarni K; Aguilar MI; Yarovsky I
J Phys Chem B; 2021 Mar; 125(10):2533-2550. PubMed ID: 33657325
[TBL] [Abstract][Full Text] [Related]
10. An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.
Guo Y; He W; Mou H; Zhang L; Chang J; Peng S; Ojha A; Tavora R; Parcells MS; Luo G; Li W; Zhong G; Choe H; Farzan M; Quinlan BD
mBio; 2021 May; 12(3):. PubMed ID: 33975938
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.
Qiao B; Olvera de la Cruz M
ACS Nano; 2020 Aug; 14(8):10616-10623. PubMed ID: 32806067
[TBL] [Abstract][Full Text] [Related]
12. Dual nature of human ACE2 glycosylation in binding to SARS-CoV-2 spike.
Mehdipour AR; Hummer G
Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33903171
[TBL] [Abstract][Full Text] [Related]
13. Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides.
Maas MN; Hintzen JCJ; Löffler PMG; Mecinović J
Chem Commun (Camb); 2021 Apr; 57(26):3283-3286. PubMed ID: 33651072
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the Neutralizing Activity of Antibodies Targeting Open or Closed SARS-CoV-2 Spike Protein Conformations.
Cia G; Pucci F; Rooman M
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216194
[TBL] [Abstract][Full Text] [Related]
15. Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants.
Upadhyay V; Lucas A; Panja S; Miyauchi R; Mallela KMG
J Biol Chem; 2021 Oct; 297(4):101208. PubMed ID: 34543625
[TBL] [Abstract][Full Text] [Related]
16. A Collection of Designed Peptides to Target SARS-CoV-2 Spike RBD-ACE2 Interaction.
Fernandez-Fuentes N; Molina R; Oliva B
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769056
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for the different states of the spike protein of SARS-CoV-2 in complex with ACE2.
Yan R; Zhang Y; Li Y; Ye F; Guo Y; Xia L; Zhong X; Chi X; Zhou Q
Cell Res; 2021 Jun; 31(6):717-719. PubMed ID: 33737693
[No Abstract] [Full Text] [Related]
18. Does the SARS-CoV-2 Spike Protein Receptor Binding Domain Interact Effectively with the DPP4 (CD26) Receptor? A Molecular Docking Study.
Cameron K; Rozano L; Falasca M; Mancera RL
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209788
[TBL] [Abstract][Full Text] [Related]
19. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana.
Rattanapisit K; Shanmugaraj B; Manopwisedjaroen S; Purwono PB; Siriwattananon K; Khorattanakulchai N; Hanittinan O; Boonyayothin W; Thitithanyanont A; Smith DR; Phoolcharoen W
Sci Rep; 2020 Oct; 10(1):17698. PubMed ID: 33077899
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library.
Bell BN; Powell AE; Rodriguez C; Cochran JR; Kim PS
Protein Sci; 2021 Apr; 30(4):716-727. PubMed ID: 33586288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
